Panacea Life Sciences Holdings, Inc. announced that the Company has expanded its softgel manufacturing expertise into the nutraceutical space and was quickly awarded eight purchase orders to fill what it believes to be a clear void in the industry. The aggregate value of the purchase orders is expected to generate approximately $500,000 in revenues for the Company in the remainder of the 2022 fiscal year. Panacea can produce up to 1 million softgels in a daily shift depending on the ingredients and the size of the softgel.

In addition, Panacea offers a full line of services for its customers including cannabinoid raw materials, formulation research and design, liquid fill capabilities, bottling and labeling, and fulfillment services.